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Marburg virus (MBGV), for which no vaccines or treatments currently exist, causes an acute hemorrhagic fever with a high
mortality rate in humans. We previously showed that immunization with either killed MBGV or a glycoprotein (GP) subunit
prevented lethal infection in guinea pigs. In the studies reported here, an RNA replicon, based upon Venezuelan equine
encephalitis (VEE) virus, was used as a vaccine vector; the VEE structural genes were replaced by genes for MBGV GP,
nucleoprotein (NP), VP40, VP35, VP30, or VP24. Guinea pigs were vaccinated with recombinant VEE replicons (packaged into
VEE-like particles), inoculated with MBGV, and evaluated for viremia and survival. Results indicated that either GP or NP were
protective antigens while VP35 afforded incomplete protection. As a more definitive test of vaccine efficacy, nonhuman
primates (cynomolgus macaques) were inoculated with VEE replicons expressing MBGV GP and/or NP. Three monkeys
received packaged control replicons (influenza HA); these died 9 or 10 days after challenge, with typical MBGV disease.
MBGV NP afforded incomplete protection, sufficient to prevent death but not disease in two of three macaques. Three
monkeys vaccinated with replicons which expressed MBGV GP, and three others vaccinated with both replicons that
expressed GP or NP, remained aviremic and were completely protected from disease.
INTRODUCTION
Marburg virus (MBGV) was first recognized in 1967,
when an outbreak of hemorrhagic fever in humans oc-
curred in Germany and Yugoslavia after the importation
of infected monkeys from Uganda (Martini and Siegert,
1971; Smith et al., 1967). Thirty-one cases of MBGV hem-
orrhagic fever were identified that resulted in seven
deaths. The filamentous morphology of the virus was
later recognized to be characteristic, not only of addi-
tional MBGV isolates, but also of Ebola virus (EBOV)
(Johnson et al., 1977; Pattyn et al., 1977; Smith et al.,
1982). MBGV and EBOV are now known to be distinctly
different lineages in the family Filoviridae, within the viral
order Mononegavirales (Kiley et al., 1982; Feldmann and
Klenk, 1996).
Few natural outbreaks of MBGV disease have been
recognized, and all proved self-limiting with no more
than two cycles of human-to-human transmission. How-
ever, the actual risks posed by MBGV to global health
cannot be assessed because factors which restrict the
virus to its unidentified ecological niche in eastern Africa,
and those that limit its transmissibility, remain unknown
(Feldmann and Klenk, 1996). Concern about MBGV is
further heightened by its known stability and infectivity in
aerosol form (Belanov et al., 1996; Frolov and Gusev Iu,
1996). Thus laboratory research on MBGV is necessarily
performed at the highest level of biocontainment. To
minimize future risk, our primary interest has been the
identification of appropriate antigens and vaccine strat-
egies that can provide immunity to MBGV.
Early efforts to demonstrate the feasibility of vaccina-
tion against MBGV were only partially successful, as
inoculation with Formalin-inactivated viruses only pro-
tected about half the experimental animals (guinea pigs
or nonhuman primates) from fatal disease (Ignat’ev et al.,
1991, 1996). We recently demonstrated that the MBGV GP,
cloned into a baculovirus vector and expressed as a
soluble antigen to be administered in adjuvant, was
sufficient to protect most but not all guinea pigs from
lethal MBGV challenge (Hevey et al., 1997). In addition,
purified, 60Co-irradiated virus, administered in adjuvant,
completely protected guinea pigs from challenge with
either of two different strains of MBGV, thus setting a
standard for future, more practicable, vaccine candidates
(Hevey et al., 1997). Experiences with EBOV vaccines
have been similar to those with MBGV, reinforcing the
difficulties of classical approaches (Lupton et al., 1980).
Recent efforts to develop EBOV vaccines, using three
distinctly different approaches (vaccinia recombinants,
VEE replicon, and naked DNA) to achieve viral antigen
expression in cells of vaccinated animals, showed that
nucleoprotein (NP) as well as GP protected BALB/c mice
(VanderZanden et al., 1998), whereas protection of
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guinea pigs by NP was unsuccessful (Gilligan et al.,
1997, Pushko et al., 1997a) or equivocal (Xu et al., 1998).
Contemporary immunological wisdom predicts that
protective responses to ‘‘internal’’ viral proteins, i.e.,
those inaccessible to antibodies (which, in the case of
MBGV, presumptively includes all proteins other than
GP), are best imparted by protein expression from within
host cells. Therefore in this study a vaccine-delivery
system based on a Venezuelan equine encephalitis
(VEE) virus replicon was used to identify candidate pro-
tective antigens in addition to MBGV GP. In this vaccine
strategy, a gene coding for a protein of interest is cloned
in place of the VEE virus structural genes; the result is a
self-replicating RNA molecule that encodes its own rep-
licase and transcriptase functions and in addition makes
abundant quantities of mRNA encoding the foreign pro-
tein. When replicon RNA is transfected into eukaryotic
cells along with two helper RNAs that express the VEE
structural proteins (glycoproteins and nucleocapsid), the
replicon RNA is packaged into VEE virus-like particles by
the VEE virus structural proteins, which are provided in
trans. Since the helper RNAs lack packaging signals
necessary for further propagation, the resulting VEE rep-
licon particles (VRPs) that are produced are infectious for
one cycle but are defective thereafter. Upon infection of
an individual cell with a VRP, an abortive infection occurs
in which the infected cell produces the protein of interest
in abundance, is ultimately killed by the infection, but
does not produce any viral progeny (Pushko et al.,
1997b).
Irrespective of how encouraging filovirus vaccine re-
sults may appear in guinea pigs or mice, protection of
nonhuman primates is widely taken as the more defini-
tive test of vaccine potential for humans. Low-passage
viral isolates from fatal human cases of MBGV or EBOV
tend to have uniform lethality in nonhuman primates but
not in guinea pigs or mice. Small animal models with
fatal disease outcomes have been achieved only with a
subset of filovirus isolates and only then by multiple
serial passages in the desired host (Hevey et al., 1997;
Bray et al., 1998; Connolly et al., 1998; Xu et al., 1998).
While highly useful for identification and initial charac-
terization of vaccine candidates, guinea pig and murine
models remain somewhat suspect with regard to the
possibility that protection in such animals is easier to
achieve than in nonhuman primates and, by inference, in
humans. For example, with MBGV, peak viremias and
viral titers in organs are more than 100 times higher in
nonhuman primates than in guinea pigs. Results shown
here demonstrate that the VEE replicon is a potent tool
for vaccination with MBGV antigens. Guinea pigs were
protected by vaccination with packaged replicons that
expressed GP or by either of two replicons that ex-
pressed internal MBGV antigens (NP and VP35). GP
expressed from the VEE replicon elicited an even more
robust immunity than was achieved previously with a
baculovirus-produced soluble GP administered in adju-
vant. When results were extended to nonhuman pri-
mates, complete protection with GP was demonstrated.
The data shown here constitute the most emphatic proof
to date that an efficacious vaccine for MBGV is feasible
and define candidate antigens for such a vaccine.
RESULTS
Analysis of protein products synthesized after
infection of Vero cells with VEE replicons that
expressed MBGV proteins
Results of indirect immunofluorescence assay (IFA)
analyses of Vero cells infected with different recombi-
nant VEE replicons expressing MBGV proteins are
shown in Fig. 1. Expression of the indicated protein
products was detected both with polyclonal guinea pig
anti-MBGV and with monoclonal antibodies (MAbs) spe-
FIG. 1. Indirect immunofluorescence of Vero cells infected with packaged VEE replicons expressing the indicated antigens.
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cific for the indicated MBGV proteins or, in the case of
VP24 (for which no MAbs were available), with conva-
lescent serum from a monkey that had survived infection
with MBGV. There were distinct staining patterns for
several of the expressed proteins. MBGV GP was ob-
served as a plasma membrane fluorescence, while the
GPDTM provided a more diffuse cytoplasmic staining.
These different staining patterns were not unexpected as
GPDTM, which lacks the hydrophobic transmembrane
region of GP, is a secreted product. MBGV NP and VP35
formed discrete patterns in the cytoplasm of cells. MBGV
VP40 demonstrated a more diffuse cytoplasmic staining
pattern. MBGV VP30 was present in unique large glob-
ules staining in the cytoplasm of cells. MBGV VP24
staining was typically perinuclear. In summary, IFA
served to assure that the appropriate antigen was ex-
pressed in a given preparation; it highlighted staining
patterns, which demonstrated the localization of the ex-
pressed MBGV proteins in Vero cells; and it served as
the basis for the assay whereby 10-fold dilutions of VRPs
were quantitated for infectivity, as focus forming units
(FFU).
Expression, antigenicity, and size determination of the
MBGV proteins were confirmed by immunoprecipitation
and gel electrophoresis. The results obtained from ex-
pression of MBGV GP, GPDTM, NP, and VP40 in Vero
cells are shown in Fig. 2. Products of the expected sizes
were specifically immunoprecipitated from replicon-in-
fected cell lysates. Glycosylation of MBGV GP more than
doubles the predicted size of the peptide chain and
typically results in a heterogeneous array of posttrans-
lationally modified products (Feldmann et al., 1991, 1994),
especially in GP from cell lysates, as shown in Fig. 2,
lane 1. As expected and shown previously in the bacu-
lovirus system, GPDTM was secreted and thus present
in the supernatant of replicon-infected cells (Fig. 2, lane
3). Appropriately, both the cell-associated (lane 2) and
secreted (lane 3) forms of GPDTM appeared smaller than
the largest forms of GP (lane 1). The secreted form of
GPDTM appeared larger and somewhat more homoge-
neous than the same molecule from cell lysates, as
noted previously (Hevey et al., 1997) (compare Fig. 2,
lanes 2 and 3). This difference likely reflects the more
complete glycosylation of the secreted product com-
pared to partially glycosylated forms of this protein ex-
pected to be present in the cell. In this gel, and with
considerably less intensity in other preparations, an un-
identified protein of approximately 46 kDa, which can be
immunoprecipitated with GP-specific monoclonal anti-
bodies (not shown), is evident in MBGV virions (Fig. 2,
lane 9). Although it remains to be confirmed, this product
may be the glycosylated form of a putative 27-kDa cleav-
age product of GP, reported to be the result of a post-
translational, furin-mediated cleavage of GP (Volchkov et
al., 1998). Replicon-expressed MBGV NP (Fig. 2, lanes
4–6) and VP40 (Fig. 2, lanes 7–8) comigrated with the
authentic proteins present in purified MBGV virions. In
other experiments, the reactivity with polyclonal or MAbs
and the authentic electrophoretic migrations of the re-
maining replicon-expressed MBGV proteins (VP30, VP35,
and VP24) were similarly demonstrated (data not shown).
Protective efficacy of VEE replicons expressing
MBGV proteins in strain 13 guinea pigs
Groups of strain 13 guinea pigs were inoculated with
packaged recombinant VEE replicons expressing indi-
vidual MBGV proteins and later challenged with 103.3
LD50 guinea pig-adapted MBGV subcutaneously. Results
are shown in Table 1. MBGV GP protected guinea pigs
from both death and viremia when administered as a
three-dose regimen. In addition, no reduction in efficacy
or potency was observed when a two-dose regimen was
instituted, and significant efficacy was observed even
when a single dose of 106 FFU of VRP-expressing MBGV
GP was used as an immunogen. The efficacy of either
the two- or three-dose vaccine schedule was further
demonstrated by the observation that no boost in post-
challenge ELISA titers were observed. This result sug-
gested minimal antigen exposure after challenge with
MBGV and thus robust or even sterile immunity in these
animals. MBGV GPDTM, which was previously shown to
be protective as a vaccine when produced from insect
cells, also protected guinea pigs from death and viremia
when delivered in a VEE virus replicon. Again, there were
no increases in postchallenge ELISA titers in the group
of animals immunized with GPDTM, thus no differences
FIG. 2. Immunoprecipitation of MBGV proteins expressed from an
alphavirus replicon in Vero cells using convalescent guinea pig poly-
clonal anti-MBGV serum. Lane 1, cell lysate from Vero cells infected
with MBGV GP replicon; lane 2, cell lysate from Vero cells infected with
MBGV GPDTM replicon; lane 3, supernatant from Vero cells infected
with MBGV GPDTM replicon; lanes 4–6, cell lysate from Vero cells
infected with various clones of MBGV NP replicon; lanes 7–8, cell
lysate from Vero cells infected with various clones of MBGV VP40
replicon; lane 9, sucrose gradient-purified 35S-labeled MBGV, *, an
unidentified 46- to 50-kDa protein observed in virion preparations.
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were discerned in the vaccine efficacy of membrane-
bound versus soluble GP.
In the experiment shown, MBGV NP protected all vac-
cinated guinea pigs from both viremia and death, while
MBGV VP35 vaccination resulted in five of six animals
surviving, but four of the five survivors were viremic 7
days postinfection. None of the other MBGV viral pro-
teins cloned into VEE replicons evoked significant pro-
tection against a lethal challenge with MBGV. Thus the
proteins that showed the most promise as vaccine can-
didates in the guinea pig model were MBGV GP and NP.
Cumulative results from this and additional experiments
(not shown) in strain 13 guinea pigs inoculated three
times with VRPs demonstrated complete survival with
GP (18/18) and less complete protection with NP (16/18)
and VP35 (13/18) as compared with controls (2/24).
Protection of cynomolgus monkeys vaccinated with
recombinant VEE replicons expressing either MBGV
GP and/or NP
Encouraged by the success in vaccinating guinea pigs
against MBGV, we evaluated the ability of these same
VEE replicons to protect cynomolgus macaques from
lethal MBGV infection. The monkeys received 10-fold
higher doses of replicons but on an identical schedule
as tested in the guinea pigs. Four groups contained three
monkeys each. One group received VRPs that expressed
MBGV GP; a second group received VRPs that ex-
pressed MBGV NP; a third group received a mixture of
MBGV GP and MBGV NP VRPs; and a fourth received
VRPs that expressed a control antigen (influenza HA)
irrelevant to MBGV immunity. Anti-MBGV ELISA antibody
titers were monitored throughout the experiment.
All animals that received VEE replicons expressing
MBGV GP, either alone or in combination with MBGV NP,
survived challenge with 8000 PFU MBGV without any
observed signs of illness (Table 2). Of the three animals
vaccinated with MBGV NP, one died 8 days after chal-
lenge from MBGV disease. The other two NP recipients
displayed signs of illness 7–9 days after challenge but
eventually recovered. One NP-inoculated survivor had a
relatively mild disease (slightly reduced activity and re-
sponsiveness), while the other had severe disease,
which included obvious petechiae, loss of weight, re-
duced activity, and fever. All control animals succumbed,
with clinical signs first noted on Day 7 or 8, and deaths
occurring on Days 9 or 10 postchallenge.
TABLE 1






Day 7 Day 64 Viremiae V/Tf MDDg
GP 3 6/6** 4.21 3.80 ,1.7 0/6 —
GP 2 6/6** 4.30 4.06 ,1.7 0/6 —
GP 1 5/6* 2.89 4.19 4.1 1/6 9
NP 3 6/6** 3.38 3.94 ,1.7 0/6 —
VP40 3 1/6 2.83 2.68 4.5 5/6 10
GPDTM 3 6/6** 3.93 3.65 ,1.7 0/6 —
VP35 3 5/6* 1.99 3.75 3.7 5/6 13
VP30 3 0/6 2.23 — 5.8 6/6 10
VP24 3 1/6 ,1.5 4.31 5.6 6/6 11
Lassa NP 3 1/6 ,1.5 4.19 6.0 5/6 10
None — 1/6 ,1.5 4.25 5.2 5/6 11
a Guinea pigs were challenged with 3 Log10 PFU guinea pig adapted MBGV (Musoke) subcutaneously.
b Endpoint titer of equal volumes of serum pooled from animals in each group against MBGV Musoke.
c Each replicon doses consisted of 1 3 106 FFU.
d Survivors/Total (S/T) on Day 30 postinfection. **P , 0.01, *P , 0.05.
e Viremia (Log10 PFU/ml) Day 7 postinfection. Where $2 animals were viremic, a GMT was calculated.
f Viremic animals/total (V/T) on Day 7 postinfection. All animals that died were viremic.
g Mean day of death.
TABLE 2
Protection of Replicon-Inoculated Cynomolgus Macaques from
Lethal Challenge with Marburg Virus (Musoke Isolate)a
Repliconb Survival/total Sick/totalc Day of death
GP 3/3* 0/3 —
NP 2/3 3/3 8
GP 1 NP 3/3* 0/3 —
Influenza HA 0/3 3/3 9, 9, 10
a Monkeys were challenged with 8000 PFU MBGV (Musoke) subcu-
tanously. Surviving animals remain healthy .90 days postchallenge.
*P 5 0.05.
b Antigen delivered by VEE replicon.
c All animals that displayed signs of illness became viremic.
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The pre- and postchallenge ELISA antibody titers of
the cynomolgus macaques are shown in Fig. 3. All ani-
mals inoculated with replicons that expressed MBGV
proteins demonstrated prechallenge ELISA titers to pu-
rified MBGV antigen. Of the three GP-vaccinated animals
that survived challenge, two demonstrated a modest
boost in ELISA antibody titer (10- to 30-fold) when pre-
and postchallenge samples were compared. The two
surviving NP-inoculated macaques had larger boosts in
ELISA antibody titers (100- to 300-fold) when pre- and
postchallenge samples were compared. Two of three
animals vaccinated with both GP and NP also demon-
strated 100- to 300-fold rise in ELISA titers. These obser-
vations, in conjunction with the back titration of the
MBGV challenge inoculum (8000 PFU), confirmed that all
groups were unambiguously challenged, and that two
monkeys had particularly robust immunity that appar-
ently restricted virus replication below an immunogenic
threshold.
A plaque reduction neutralization assay was per-
formed on pre- and postchallenge serum samples. No
neutralization activity was observed, at 1:20 or higher
dilutions, in any sample. It should be noted that it is
frequently difficult to demonstrate filovirus-neutralizing
antibody in vitro; however, antibodies may nonetheless
be relevant in vivo (Hevey et al., 1998), perhaps via
mechanisms other than classical neutralization (Schmal-
john et al., 1982).
The viremia levels in each of the monkeys at several
time points after MBGV challenge are shown in Fig. 4.
The data illustrate the profound differences between
lethally infected control animals and healthy survivors.
Most striking, none of the animals vaccinated with GP,
either alone or in combination with NP, had infectious
MBGV virus in their sera that was detectable by plaque
assay. Animals vaccinated with a replicon expressing
influenza HA were all viremic by Day 3 postchallenge
and demonstrated sharp rises in MBGV viremia levels
which peaked at 7.5–8.0 Log10 PFU/ml on Day 7 postin-
fection. Among monkeys vaccinated with NP, one died
with viremias indistinguishable from controls. In contrast,
the two NP-vaccinated monkeys that recovered had peak
viremias that were diminished $1000-fold compared
with controls. By Day 10 postinfection, the NP-vaccinated
monkey with the milder illness had no detectable vire-
mia, while the more severely affected monkey still had
;4.5 Log10 PFU/ml virus. By Day 17 postinfection, no
viremia was detectable in either of the surviving NP-
vaccinated animals.
Additional measures of vaccine-mediated protection
Upon necropsy of the control and the unprotected
NP-inoculated monkeys, MBGV titers in their livers were
9.2, 9.7, 9.4, and 9.6 Log10 PFU/g. Virus was detected in
all other organs examined as well and although abun-
dant, was at least 10-fold lower than in the liver. Not
surprisingly, elevated liver enzymes were the most obvi-
ous abnormal feature in clinical chemistries. As shown in
Fig. 5, unprotected monkeys had elevated AST levels by
Day 5 or 7 postinfection, and these were paralleled by
similarly profound increases in ALT and ALP (not shown).
Terminal samples were automatically rejected by the
instrument as too lipemic or hemolyzed; however, in a
previous set of control monkeys, liver enzymes had con-
tinued to ascend dramatically (not shown). With regard to
FIG. 4. Viremia level in cynomolgus monkeys inoculated with alpha-
virus replicons followed by challenge with MBGV (Musoke). F, animals
vaccinated with VEE replicons expressing MBGV GP; r, animals vac-
cinated with VEE replicons expressing MBGV NP; f, animals vacci-
nated with a mixture of VEE replicons which expressed either MBGV
GP or NP; , animals vaccinated with VEE replicons expressing influ-
enza HA. Open symbols represent animals that died. Closed symbols
represent animals that lived. Dotted line notes the lower limit of detec-
tion of this plaque assay (1.7Log10 PFU/ml).
FIG. 3. Anti-MBGV ELISA titers of cynomolgus monkeys after three
inoculations with recombinant replicon 17 days before or after chal-
lenge with MBGV. Prechallenge samples were obtained 17 days before
challenge, while postchallenge samples were obtained 17 days after
challenge. GP, animals inoculated with VEE replicons expressing
MBGV GP; NP, animals inoculated with VEE replicon expressing MBGV
NP; GP1NP, animals inoculated with a mixture of VEE replicons ex-
pressing either MBGV GP or NP; Flu HA, animals inoculated with VEE
replicon expressing influenza HA. Numbers inside each symbol repre-
sent the same individual in each group. Symbols filled in with cross-
hatch marks signify animals that died from infection.
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vaccine-mediated protection, it is instructive that the two
NP-inoculated survivors exhibited marked but transient
rises in their liver enzymes (Fig. 5), which is consistent
with their viremias and signs of MBGV disease. Also, the
more severely affected NP-inoculated survivor exhibited
a transient rise in urea nitrogen and creatinine (not
shown), coincident with recovery and viral clearance.
This may have been due to virus-antibody complexes
perturbing kidney function or to direct viral damage to the
organs. In contrast, the six monkeys vaccinated with GP
exhibited either a minimal rise at one time point (i.e., the
one GP animal shown in Fig. 5) or no significant in-
creases in liver enzymes at any time evaluated. Other
clinical chemistries and hematological findings re-
mained normal in MBGV-inoculated macaques vacci-
nated previously with GP or GP1NP, in contrast with
control monkeys that exhibited the expected profound
end-stage abnormalities in both hematological and
chemistry measurements (Johnson et al., 1995).
DISCUSSION
To our knowledge, this is the first report of any filovirus
vaccine shown to be completely efficacious in nonhu-
man primates. Before these observations, we were cau-
tiously optimistic about the overall feasibility of an effi-
cacious vaccine for MBGV but were also concerned that
proofs of filovirus vaccine concepts in guinea pigs may
not necessarily forecast success in nonhuman primates
and, by inference, in humans. Results presented here
defined GP, possibly in combination with NP, as candi-
date antigens for a MBGV vaccine and demonstrated
that nearly complete immunity is achievable in nonhu-
man primates.
We chose an alphavirus replicon based on VEE virus
to deliver the antigens of interest. This method of vacci-
nation has several advantages (Pushko et al., 1997b),
including the ability to produce large quantities of anti-
gen in situ, so that native processing of the antigens
might evoke a broad array of immune responses. In
addition, all transcription of RNA occurs in the cytoplasm
of cells, which avoids RNA splicing problems sometimes
observed when proteins of RNA viruses are expressed
from the nucleus. Moreover, VEE replicons have proven
stable after packaging into VRPs. In addition to robust
antibody induction, alphavirus replicons have been dem-
onstrated to elicit cytotoxic T lymphocytes in mice (Zhou
et al., 1995; Caley et al., 1997). The success reported here
using VEE replicons to vaccinate monkeys against lethal
MBGV challenge justifies a more detailed analysis of the
potential of these vectors for use as human vaccines.
These analyses may include such factors as the rele-
vance of host-vector interactions that may affect vaccine
potency, overall safety of the vector, and the duration and
minimal requirements for immunity to MBGV disease
induced by this vector.
Two viral antigens demonstrated unambiguous po-
tential as protective antigens in the guinea pig model:
MBGV GP and MBGV NP. Another viral antigen, VP35,
provided significant protection from death; however,
most (5/6) animals vaccinated with VP35 exhibited
viremias 7 days after infection. Consequently, VP35
was not considered a candidate for the initial exami-
nation of vaccine efficacy in nonhuman primates.
FIG. 5. Serum AST levels in VEE replicon inoculated cynomolgus macaques after challenge with MBGV (Musoke). F, the one animal (of six)
vaccinated with VEE replicons expressing MBGV GP that exhibited AST abnormality at any time point. r, animals vaccinated with VEE replicons
expressing MBGV NP; , animals vaccinated with VEE replicon expressing influenza HA. Open symbols represent animals that died. Closed symbols
represent animals that lived. Dotted line demarks 88 U/L, which is the mean (38 U/L) plus three standard deviations of prebleed values from the 12
monkeys in this experiment.
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While none of the other viral antigens showed signif-
icant promise as protective antigens in the guinea pig
model, some were only weakly immunogenic, at least
when delivered as VRPs. Thus we have not formally
excluded the possibility that such antigens may prove
protective under different circumstances or in species
other than guinea pigs.
As a more definitive test of efficacy, the two most
promising guinea pig protective antigens from MBGV
were used to inoculate nonhuman primates either alone
or in combination. Using recombinant VEE replicons,
MBGV GP was clearly shown to be protective. The ob-
servation that none of the animals developed overt ill-
ness or viremia was conclusive proof that this vaccine
approach had protected animals from a substantial chal-
lenge dose of MBGV. However, there were some signif-
icant differences observed between guinea pigs and
cynomolgus macaques. Most notable was the observa-
tion that two-thirds of the GP-vaccinated monkeys dem-
onstrated rises in ELISA antibody titers following MBGV
challenge, whereas there was apparently sterile immu-
nity (i.e., no further increases in antibody titers) to viral
challenge in guinea pigs given a 10-fold lower dose of
the same vaccine. This may be attributable to the overall
higher prechallenge ELISA antibody titers observed in
guinea pigs when compared to those observed in the
monkeys (Table 1 vs Fig. 3).
The second antigen examined, MBGV NP, was less
effective at protecting nonhuman primates compared to
guinea pigs. All the monkeys inoculated with NP dis-
played signs of illness, with one animal dying in the
same time frame as control animals. All animals were
viremic, and viremia levels were predictive of outcome.
As expected, the two animals that survived illness had
large boosts in their ELISA antibody titers against MBGV
when pre- and postchallenge sera were examined.
Though not statistically significant in a group of only
three animals, MBGV NP was apparently able to provide
a measure of protection from death but not from disease
in two monkeys. We surmise that the immune response
to NP was sufficient to suppress replication of MBGV
until augmented by additional host immune responses.
The monkeys that were vaccinated with both MBGV
GP and NP demonstrated the same degree of protection
as the animals vaccinated with GP alone. No viremias
were observed at any time point, and two of three ani-
mals demonstrated postchallenge increases in ELISA
antibody titers to MBGV. These results demonstrated that
the NP replicon, equivocal by itself as a macaque vac-
cine, did not interfere with a GP-based vaccine when
protective efficacy was used as a measurement.
For these studies, in the interest of expedient vaccine
development, protection from viral disease was priori-
tized over the detailed study of immune mechanisms in
two relatively difficult animal species for immunological
studies, guinea pigs and cynomolgus macaques. It was
already clear from studies done in guinea pigs that
ELISA antibody titers to MBGV were not wholly predictive
of clinical outcome but rather one measure of immuno-
genicity of the vaccine candidate. However, it was also
known that administration of polyclonal antisera or a
neutralizing MAb could protect some guinea pigs from
lethal challenge, indicating that antibodies can play a
role in the protective response to MBGV (Hevey et al.,
1997). As for immunity to virtually all viruses, T cell
responses to MBGV are almost certainly important in
their immunoregulatory and effector functions. Indeed,
we observed protection in both guinea pigs (NP and
VP35) and nonhuman primates (NP) with antigens for
which the most logical protective mechanisms involve
cellular immunity. However, it also proved emphatically
true in the most susceptible animals—nonhuman pri-
mates—that protective immunity was elicited by an an-
tigen (GP) that theoretically favored a redundant protec-
tive response of both T cells and antibodies. For devel-
opment and licensure of vaccines for human use, it will
be necessary to understand the protective immune re-
sponses of nonhuman primates to MBGV and determine
which responses (or which combinations of them) are
most predictive of vaccine efficacy.
MATERIALS AND METHODS
Cell cultures and viruses
Vero E6 (Vero C1008, ATCC CRL 1586), Vero 76 (ATCC
CRL 1587), and BHK (ATCC CCL 10) cells were grown in
minimal essential medium with Earle’s salts supple-
mented with 10% fetal bovine serum and gentamicin (50
mg/ml). MBGV (strain Musoke) was isolated from a hu-
man case in 1980 in Kenya (Smith et al., 1982), and a
derivative of this virus (six passages in Vero 76 cells) was
used to challenge the cynomolgus monkeys. The MBGV
(Musoke) that was adapted for guinea pig lethality and
plaque-picked three times was described previously
(Hevey et al., 1997).
Construction of recombinant VEE replicons
MBGV gene clones pGem-GP, pGem-NP, pTM1-VP40,
pTM1-VP35, pTM1-VP30, and pTM1-VP24 were gener-
ously provided by Heinz Feldmann and Anthony Sanchez
(Centers for Disease Control and Prevention, Atlanta,
GA). VEE replicon and shuttle vector as well as the
replicons that express Lassa virus NP and Flu HA were
previously described (Pushko et al., 1997b). The MBGV
GP gene from pGem-GP was excised with SalI and
subcloned into the SalI site of the shuttle vector by using
standard techniques (Sambrook et al., 1989). A clone
with the MBGV GP gene in the correct orientation was
excised with ApaI and NotI, and this fragment was
cloned into the ApaI and NotI sites of the VEE replicon
plasmid.
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Construction of pBluescript-KS(1)-GPDTM, a deletion
mutant of MBGV from which the C-terminal 39 amino
acids (transmembrane region and cytoplasmic tail) of
MBGV GP were removed, was previously described
(Hevey et al., 1997). Here, the MBGV GPDTM gene was
excised from pBluescript-KS(1) with HindIII, and the re-
sulting fragment ligated into the HindIII site of the shuttle
vector. MBGV GPDTM gene was excised from the shuttle
vector using ClaI, and the resulting fragment ligated into
the VEE replicon plasmid.
The MBGV NP gene was amplified by PCR performed
with 1 ng of pGem NP as template DNA, 1 mg each of
forward (59-CCG ACC ATG GAT TTA CAC AGT TTG TTG
G-39) and reverse primer (59-CTA GCC ATG GCT GGA
CTA CAA GTT CAT CGC-39), and AmpliTaq polymerase
(GeneAmp PCR reagent kit, Perkin-Elmer, Branchburg,
NJ). The reaction conditions were: 40 cycles of 94°C for
45 s, 50°C for 45 s, and 72°C for 1 min, followed by a final
extension step at 72°C for 5 min. The product was
cloned into the pCRII vector, excized with EcoRI, then
subcloned into the shuttle vector using EcoRI sites. The
MBGV NP gene was excised with ClaI and ligated into
the VEE replicon plasmid.
The MBGV VP40, VP35, VP30, and VP24 genes were
excised from pTM1 with BamHI and ligated into the
BamHI site of the shuttle vector. These MBGV genes
were then excised from shuttle vectors using either ClaI
(VP35, VP30, and VP24) or ApaI and NotI (VP40) and
ligated into the VEE replicon plasmid.
Packaging of replicons into VEE-like particles and
determination of replicon titer
Replicon RNAs were packaged into VRPs as de-
scribed previously (Pushko et al., 1997b). Briefly, BHK
cells were cotransfected with RNA transcribed in vitro
from the replicon plasmid and from two helper plasmids,
one of which expressed VEE glycoproteins and the other
VEE capsid protein. The cell culture supernatant was
harvested approximately 30 h after transfection, and the
replicon particles were concentrated and partially puri-
fied by pelleting through a 20% sucrose cushion (SW28
rotor, 25,000 rpm, 4 h), after which they were resuspend-
ing in 1 ml PBS. To assay titers of packaged replicons,
Vero cells (105 cells per well in eight-chamber slides,
Labtek slides, Nunc Inc.) were infected with serial dilu-
tions of the replicon particles and incubated for 16–18 h
at 37°C to allow for expression of the MBGV genes. After
rinsing and fixating with acetone, antigen-positive cells
were identified by indirect immunofluorescence assay
(IFA) as described previously (Schmaljohn et al., 1995).
The antibodies used included MAbs specific for MBGV
GP (II-7C11), NP (III-5F8), VP40 (III-1H11), VP35 (XBC04-
BG06), and VP30 (III-5F11 and 5F12) (Hevey et al., 1997).
To detect VP24 antigen, a monkey anti-MBGV serum was
used, a monkey anti-Lassa serum was used to detect
expression of Lassa NP in cells, and influenza HA was
detected with serum from a mouse immunized with a
VEE replicon expressing influenza HA (provided by Dr.
Mary Kate Hart, USAMRIID).
Immunoprecipitation and gel electrophoresis of
proteins expressed by VEE replicons
Expressed MBGV antigens were immunoprecipitated
and analyzed by gel electrophoresis as described previ-
ously (Hevey et al., 1997). Briefly, Vero cells were infected
(m.o.i. $3) with VRP expressing a single MBGV antigen.
Complete medium was replaced 16–18 h postinfection by
methionine- and cysteine-free medium for 1 h, and
monolayers were then labeled with 35[S]methionine and
cysteine for 4 h. Convalescent guinea pig anti-MBGV
(Group 1, Table 5, in Hevey et al., 1997) was used to
immunoprecipitate MBGV-specific proteins from the re-
sulting cell lysates.
Vaccination of guinea pigs with VEE replicons
expressing MBGV proteins
Inbred strain 13 guinea pigs (maintained as a colony at
USAMRIID) were inoculated subcutaneously with 106
focus-forming units (FFU) of VRP in a total volume of 0.5
ml administered at two dorsal sites. Guinea pigs were
anesthetized and bled, and those that received two or
three doses of replicon were inoculated (as described for
the first vaccine dose) 28 days after the primary vacci-
nation. Guinea pigs were anesthetized and bled again 28
days later, and animals that received three doses of
replicons were inoculated, as described above. Animals
were anesthetized and bled 21 days later, and chal-
lenged 7 days after the last bleed with 103.0 plaque
forming units (PFU) (ca. 2000 LD50) guinea-pig-adapted
MBGV. Animals were examined daily for signs of illness.
Heparinized plasma was obtained from the retroorbital
sinus of anesthetized animals 7 days postinfection for
assay of viremia. Surviving guinea pigs were observed
for at least 30 days after challenge, then anesthetized,
and exsanguinated. Viremia titers were measured by
plaque assay on Vero E6 cells.
Vaccination of cynomolgus monkeys with replicons
Twelve cynomolgus macaques (Macaca fascicularis),
11 females and 1 male, ranging from 2.8 to 4.5 kg, were
inoculated subcutaneously with 107 FFU of VRP in a total
volume of 0.5 ml at one site. Monkeys were anesthetized
with ketamine, bled, and inoculated (as described for the
first vaccine dose) 28 days after the primary injection,
and again 28 days after the second. Animals were anes-
thetized and bled 21 days after the third vaccine dose,
then were challenged 14 days later with 103.9 PFU MBGV
subcutaneously. Here and in guinea pig experiments, the
inoculum was back-titrated to ensure proper dose deliv-
ery. Animals were examined daily by the attending vet-
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erinarian for signs of illness and given buprenorphine
(Buprenex) at a dosage of 0.01 mg/kg body weight, BID,
to provide analgesia upon signs of distress. Of the un-
protected animals, three succumbed abruptly, while one
was euthanized in extremis. A detailed clinical evalua-
tion, serum for viremia determination and blood chemis-
tries, as well as EDTA blood was obtained from anes-
thetized animals 17 days before and 3, 5, 7, 10, 17, and 32
days postinfection. Viremia was measured by plaque
assay on Vero E6 cells.
MBGV ELISA and infectivity assays
Antibody titers in guinea pig plasmas or monkey sera
were determined by an indirect ELISA as described pre-
viously (Hevey et al., 1997). Briefly, antigen consisting of
purified, irradiated virus was coated directly onto PVC
plates and serial dilutions of test serum were added to
wells containing antigen. The presence of bound anti-
body was detected by use of the appropriate horseradish
peroxidase conjugated anti-species antibody (HPO-goat-
anti-guinea pig IgG H1L; HPO-goat-anti-monkey IgG
H1L). Endpoint of reactivity was defined as the dilution
at which OD405 was 0.2 as determined by extrapolation
of a four parameter curve fit (SOFTmax, Molecular De-
vices Corp.) of background-subtracted mean OD versus
dilution. Results shown in any table or figure are from a
single assay to allow more valid comparison of end-
points. Plaque assays were performed on Vero E6 cells
with a semisolid overlay on serial dilutions of samples.
Viral plaques were visualized by staining viable cells
with Neutral red 6–7 days postinfection. To measure
plaque reduction neutralization, equal volumes of a virus
stock (target plaque dose was 100 PFU) and serum
diluted in cell culture medium were mixed and incubated
at 37°C for 1 h. The resulting sample was assayed by
plaque assay on Vero E6 cells for more than a 50%
reduction in PFU compared to control samples.
Clinical laboratory assays
For nonhuman primate studies, hematological results
were obtained with a Coulter instrument, and differential
counts were performed manually. Clinical chemistry re-
sults were obtained with a Piccolo analyzer (Abaxis, Inc.)
using the diagnostic panel General Chemistry 12, which
measures alanine aminotransferase (ALT), albunin, alka-
line phosphatase (ALP), amylase, aspartate aminotrans-
ferase (AST), calcium, cholesterol, creatinine, glucose,
total bilirubin, total protein, and urea nitrogen.
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